Icosavax Identifies Reason its COVID-19 Vaccine Failed, Looks Toward Future

Icosavax has just wrapped up an investigation into the disappointing results of its COVID-19 vaccine candidate, IVX-411, finding that instability issues were at fault. The receptor binding domain of the soccer ball-shaped “virus-like particle” degraded at the recommended storage temps of 2-8°C. The instability proved to diminish the effect of the vaccine in mice studies.

According to , “While analysts had begun to question the biotech’s entire platform after the failure of the Covid-19 vaccine, some are now seemingly reversing course. ‘The analysis suggests that there is little read through from IVX-411 to IVX-A12 program or the rest of ICVX’s platform,’ said Cowen analyst Phil Nadeau in a note.”

To read more, click here.

(Source: Endpoints News, July 29th, 2022)